natgillin/translations-raw huggingface dataset:
LOVENOX (and associated names) 10,000 IU (100 mg)/10 mL is used to stop blood clots forming in the tubes of your dialysis machine (used for people with severe kidney problems). 
Zdravilo LOVENOX (in povezana imena) 10.000 i.e. (100 mg)/10 mL se uporablja za preprečitev nastajanja krvnih strdkov v cevkah dializne naprave (uporablja se pri osebah, ki imajo hude težave z ledvicami).
Do not expel the air bubble from the syringe before the injection to avoid the loss of drug when using pre-filled syringes. 
V primeru uporabe napolnjene injekcijske brizge iz nje pred injiciranjem ne poskušajte odstraniti zračnega mehurčka, da ne pride do izgube zdravila.
METHOD OF ADMINISTRATION SC / IV 
POSTOPEK UPORABE s.c./i.v.
INFORMATION IN BRAILLE LOVENOX 10 x 4,000 IU (10 x 40 mg) Pen 
PODATKI V BRAILLOVI PISAVI LOVENOX 10 x 4,000 IU (10 x 40 mg) peresnik
Changing of anticoagulant treatment - Changing from LOVENOX (and associated names) to blood thinners called vitamin-K antagonists (e.g. warfarin) 
Menjava antikoagulantnih zdravil - Prehod z zdravila LOVENOX (in povezana imena) na sredstva za redčenje krvi, imenovana antagonisti vitamina K (npr. varfarin)
Besides the anticoagulant effects of enoxaparin sodium, there was no evidence of adverse effects at 15 mg/kg/day in the 13-week SC toxicity studies both in rats and dogs and at 10 mg/kg/day in the 26week SC and IV toxicity studies both in rats, and monkeys. 
Poleg antikoagulantnega učinka natrijevega enoksaparinata niso ugotovili znakov neželenih učinkov ne v 13-tedenski študiji toksičnosti subkutane uporabe 15 mg/kg/dan pri podganah in psih ne v 26-tedenskih študiji toksičnosti subkutane in intravenske uporabe 10 mg/kg/dan pri podganah in opicah.
Common (may affect up to 1 in 10 people) 
Pogosti (pojavijo se lahko pri do 1 od 10 oseb)
Heparins can suppress adrenal secretion of aldosterone leading to hyperkalaemia (see section 4.8), particularly in patients such as those with diabetes mellitus, chronic renal failure, pre-existing metabolic acidosis, taking medicinal products known to increase potassium (see section 4.5). 
Heparini lahko zavrejo izločanje aldosterona iz nadledvičnih žlez in lahko zaradi tega povzročijo hiperkaliemijo (glejte poglavje 4.8), zlasti pri bolnikih s sladkorno boleznijo, kronično odpovedjo ledvic ali obstoječo metabolično acidozo in pri uporabnikih zdravil, ki zvišujejo kalij (glejte poglavje
Your doctor will request you perform blood tests called INR and tell you when to stop LOVENOX (and associated names) accordingly. 
Zdravnik vam bo naročil, da opravite preiskavo krvi, imenovano INR, in vam bo glede na to povedal, kdaj naj nehate uporabljati zdravilo LOVENOX (in povezana imena).
- Other thrombolytics (e.g. alteplase, reteplase, streptokinase, tenecteplase, urokinase) and anticoagulants. 
- drugi trombolitiki (npr. alteplaza, reteplaza, streptokinaza, tenekteplaza, urokinaza) in antikoagulansi.
LOVENOX (and associated names) contains the active substance called enoxaparin sodium that is a low molecular weight heparin (LMWH). 
Zdravilo LOVENOX (in povezana imena) vsebuje zdravilno učinkovino natrijev enoksaparinat, ki je nizkomolekularni heparin (NMH).
Intracranial haemorrhage, Retroperitoneal haemorrhage 
Intrakranialna krvavitev, retroperitonealn a krvavitev
For acute STEMI, treatment is to be initiated with a single IV bolus injection immediately followed by a SC injection. 
Zdravljenje akutnega STEMI je treba začeti z eno intravensko bolusno injekcijo, ki ji neposredno sledi subkutana injekcija.
Therefore, for patients on enoxaparin sodium, the PCI was to be performed on enoxaparin sodium (no switch) using the regimen established in previous studies i.e. no additional dosing, if last SC administration given less than 8 hours before balloon inflation, IV bolus of 30 IU/ kg (0.3 mg/kg) enoxaparin sodium, if the last SC administration given more than 8 hours before balloon inflation. 
Zato je morala biti za bolnike na natrijevem enoksaparinatu PKI narejena na natrijevem enoksaparinatu (brez menjave) in po shemi, oblikovani v predhodnih študijah tj. brez dodatnega odmerjanja, če je bila zadnja subkutana uporaba manj kot 8 ur pred balonskim širjenjem, in intravenski bolus 30 i.e./kg (0,3 mg/kg) natrijevega enoksaparinata, če je bila zadnja subkutana uporaba več kot 8 ur pred balonskim širjenjem.
See “Do not use LOVENOX (and associated names)”. 
Glejte tudi "Ne uporabljajte zdravila LOVENOX (in povezana imena)".
Do not inject LOVENOX (and associated names) into a muscle. 
Zdravila LOVENOX (in povezana imena) ne injicirajte v mišico.
Excipient(s) with known effect: benzyl alcohol. 
Pomožne snovi z znanim učinkom: benzilalkohol.
All Treated DVT Patients with or without PE 
Vsi zdravljeni bolniki z GVT, s PE ali brez nje
In these patients, careful clinical monitoring is advised, and biological monitoring by anti-Xa activity measurement might be considered (see sections 4.2 and 5.2). 
Pri teh bolnikih je priporočljiv natančen klinični nadzor in v poštev pride biološko spremljanje z meritvijo aktivnosti anti-Xa (glejte poglavji 4.2 in 5.2).
• For acute STEMI, treatment is to be initiated with a single IV bolus injection immediately followed by a SC injection. 
• Zdravljenje akutnega STEMI je treba začeti z eno intravensko bolusno injekcijo, ki ji neposredno sledi subkutana injekcija.
For prefilled syringe PL: Instruction for use of the syringe [To be completed locally] 
Za navodilo za uporabo napolnjene injekcijske brizge: Navodilo za uporabo injekcijske brizge [Dopolnite lokalno]
Driving and using machines LOVENOX (and associated names) does not affect the ability to drive and operate machinery. 
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo LOVENOX (in povezana imena) ne vpliva na sposobnost upravljanja vozil in strojev.
SC injection Do not mix with other products. 
6.2 Inkompatibilnosti Subkutano injiciranje Ne mešajte z drugimi zdravili.
(20 mg) or 4,000 IU (40 mg) of LOVENOX (and associated names) each day. 
ali 4.000 i.e. (40 mg) zdravila LOVENOX (in povezana imena) na dan.
• LOVENOX (and associated names) is usually given by injection underneath the skin (subcutaneous). 
• Zdravilo LOVENOX (in povezana imena) se po navadi injicira pod kožo (subkutano).
After repeated SC 150 IU/kg (1.5 mg/kg) once daily dosing, mean AUC of anti-Xa activity is marginally higher at steady state in obese healthy volunteers (BMI 30-48 kg/m2) compared to nonobese control subjects, while maximum plasma anti-Xa activity level is not increased. 
Po večkratni subkutani uporabi 150 i.e./kg (1,5 mg/kg) enkrat na dan je povprečna AUC aktivnosti anti-Xa v stanju dinamičnega ravnovesja pri debelih zdravih prostovoljcih (ITM 30-48 kg/m2) malenkostno večja kot pri nedebelih kontrolnih osebah, največja raven aktivnosti anti-Xa v plazmi pa ni povečana.
• Common: Allergic reaction 
Bolezni imunskega sistema • Pogosti: Alergijska reakcija
How to store LOVENOX (and associated names) Contents of the pack and other information 
Shranjevanje zdravila LOVENOX (in povezana imena) Vsebina pakiranja in dodatne informacije
• Switch between enoxaparin sodium and direct oral anticoagulants (DOAC) For patients currently receiving enoxaparin sodium, discontinue enoxaparin sodium and start the DOAC 0 to 2 hours before the time that the next scheduled administration of enoxaparin sodium would be due as per DOAC label. 
• Prehod med natrijevim enoksaparinatom in neposrednimi peroralnimi antikoagulansi (DOAC - Direct Oral Anticoagulants) Bolnikom, ki trenutno prejemajo natrijev enoksaparinat, slednjega ukinite in uvedite DOAC od 0 do 2
INSTRUCTIONS ON USE [To be completed nationally] 
NAVODILA ZA UPORABO: [Izpolni država članica]
Instruction for use of the pen [To be completed locally] 
Navodilo za uporabo peresnika [Dopolnite lokalno]
• Your doctor will decide how long you should receive LOVENOX (and associated names). 
• Zdravnik bo določil, koliko časa morate prejemati zdravilo LOVENOX (in povezana imena).
The effect of this dose is usually sufficient for a 4-hour session; however, if fibrin rings are found, for example after a longer than normal session, a further dose of 50 IU to 100 IU/kg (0.5 to 1 mg/kg) may be given. 
Učinek tega odmerka po navadi zadošča za 4-urno dializo, a če se pojavijo fibrinski obročki, npr. po dializi, ki je daljša kot po navadi, je mogoče dati dodaten odmerek od 50 do
- Systemic salicylates, acetylsalicylic acid at anti-inflammatory doses, and NSAIDs including ketorolac, 
Med takšna zdravila spadajo na primer: - sistemski salicilati, acetilsalicilna kislina v protivnetnih odmerkih in NSAID, vključno s ketorolakom,
Enoxaparin sodium may be safely administered with normal saline solution (0.9%) or 5% dextrose in water (see section 4.2). 
Natrijev enoksaparinat je mogoče varno dati v fiziološki raztopini (0,9 % raztopina natrijevega klorida) ali 5 % raztopini glukoze v vodi (glejte poglavje 4.2).
In these patients, careful clinical monitoring is advised, and biological monitoring by anti-Xa activity measurement might be considered (see section 5.2). 
Pri teh bolnikih je priporočljiv natančen klinični nadzor in v poštev pride biološko spremljanje z meritvijo aktivnosti anti-Xa (glejte poglavjie 5.2).
• Stop blood clots from forming in your blood in the following situations: o Before and after an operation o When you have an acute illness and face period of limited mobility o When you have unstable angina (a condition when not enough blood gets to your heart) o After a heart attack 
o Pred operacijami in po njih o Če imate akutno bolezen in vas čaka obdobje omejene možnosti gibanja (mobilnosti) o Če imate nestabilno angino pektoris (motnjo, pri kateri v srce ne pride dovolj krvi) o Po srčnem infarktu
The occurrence of total and major bleeding were respectively 8.6% and 1.1% in the placebo group, 11.7% and 0.3% in the enoxaparin sodium 2,000 IU (20 mg) group and 12.6% and 1.7% in the enoxaparin sodium 4,000 IU (40 mg) group. 
Pojavljanje vseh krvavitev je bilo v skupini s placebom 8,6 %, v skupini z 2.000 i.e. (20 mg) natrijevega enoksaparinata 11,7 % in v skupini s 4.000 i.e. (40 mg) natrijevega enoksaparinata 12,6 %,
The risk of these events is higher with the use of post-operative indwelling epidural catheters, with the concomitant use of additional drugs affecting haemostasis such as NonSteroidal-Anti Inflammatory Drugs (NSAIDs), with traumatic or repeated epidural or spinal puncture, or in patients with a history of spinal surgery or spinal deformity. 
Tveganje za te učinke je večje v primeru pooperacijske uporabe stalnih epiduralnih katetrov, med sočasno uporabo dodatnih zdravil, ki vplivajo na hemostazo, npr. nesteroidnih protivnetnih zdravil (NSAID), v primeru travmatske ali ponavljajoče se epiduralne ali spinalne punkcije, ali pri bolnikih z anamnezo spinalne operacije ali spinalno deformacijo.
You should tell your doctor straight away • If you have any sign of blockage of a blood vessel by a blood clot such as : 
• Če imate kakršen koli znak zamašitve žile s krvnim strdkom, na primer:
LOVENOX (and associated names) should not be used interchangeably with other medicines belonging to the group of low molecular weight heparins. 
Zdravila LOVENOX (in povezana imena) se ne sme uporabljati medsebojno zamenljivo z drugimi zdravili iz skupine nizkomolekularnih heparinov.
Musculoskeletal, connective tissue and bone disorders • Rare: Osteoporosis* following long term therapy (greater than 3 months) 
• Redki: Osteoporoza* po dolgotrajnem zdravljenju (več kot 3 mesece)
• Spinal/Epidural anaesthesia or lumbar puncture Spinal/epidural anaesthesia or lumbar puncture must not be performed within 24 hours of administration of enoxaparin at therapeutic doses (see also section 4.3). 
• Spinalna/epiduralna anestezija ali lumbalna punkcija Spinalne/epiduralne anestezije ali lumbalne punkcije se ne sme opraviti v 24 urah po uporabi terapevtskih odmerkov natrijevega enoksaparinata (glejte poglavje 4.3).
o For patients with a high venous thromboembolism (VTE) risk who undergo abdominal or pelvic surgery for cancer an extended thromboprophylaxis up to 4 weeks is recommended. 
o Pri bolnikih z velikim tveganjem za vensko trombembolijo (VTE) s trebušno ali medenično operacijo zaradi raka je priporočljiva podaljšana tromboprofilaksa do
It may cause toxic and allergic reactions in infants up to 3 years old. 
Pri otrocih do 3. leta starosti lahko benzilakohol povzroči toksične in alergijske reakcije.
Intracranial haemorrhage, 
- huda arterijska hipertenzija,
If the last SC administration was given more than 8 hours before balloon inflation, an IV bolus of 30 IU/kg (0.3 mg/kg) enoxaparin sodium should be administered. 
Če je bil zadnji subkutani odmerek uporabljen več kot 8 ur pred balonskim širjenjem, je treba dati intravenski bolus 30 i.e./kg (0,3 mg/kg) natrijevega enoksaparinata.
- cramping pain, redness, warmth, or swelling in one of your legs - these are symptoms of deep vein thrombosis - breathlessness, chest pain, fainting or coughing up blood - these are symptoms of a pulmonary embolism 
- krčevite bolečine, pordelost, toploto ali oteklost ene noge - to so simptomi globoke venske tromboze, - težko dihanje, bolečino v prsih, omedlevico ali izkašljevanje krvi - to so simptomi pljučne embolije.
• Switch between enoxaparin sodium and vitamin K antagonists (VKA) Clinical monitoring and laboratory tests [prothrombin time expressed as the International Normalized Ratio (INR)] must be intensified to monitor the effect of VKA. 
Za nadzor nad učinkom VKA je treba poostriti klinični nadzor in laboratorijske preiskave (protrombinski čas, izražen kot internacionalno normalizirano razmerje [INR]).
• At the same time you will also be given LOVENOX (and associated names) as an injection underneath your skin (subcutaneous injection). 
• Obenem boste dobili zdravilo LOVENOX (in povezana imena) tudi v injekciji pod kožo
What LOVENOX (and associated names) is and what it is used for 
Kaj je zdravilo LOVENOX (in povezana imena) in za kaj ga uporabljamo
LOVENOX (and associated names) can be used to: 
Zdravilo LOVENOX (in povezana imena) se uporablja za:
After you have had a heart attack 
o Po srčnem infarktu
No pharmacokinetic interactions were observed between enoxaparin sodium and thrombolytics when administered concomitantly. 
Farmakokinetično medsebojno delovanje Med sočasno uporabljenim natrijevim enoksaparinatom in trombolitiki niso opazili farmakokinetičnih medsebojnih delovanj.
50,000 IU (500 mg)/5 mL 
50.000 i.e. (500 mg)/5 ml
LOVENOX (and associated names) is indicated in adults for: 
4.1 Terapevtske indikacije Zdravilo LOVENOX (in povezana imena) je indicirano pri odraslih za:
• Aspirin (also known as acetylsalicylic acid or ASA), clopidogrel or other medicines used to stop blood clots from forming 
• Acetilsalicilno kislino, klopidogrel ali druga zdravila, ki se uporabljajo za preprečevanje nastajanja krvnih strdkov
• you have high level of potassium in your blood (this may be checked with a blood test) 
• če imate v krvi visoko koncentracijo kalija (to je mogoče preveriti s preiskavo krvi) • če trenutno uporabljate zdravila, ki vplivajo na strjevanje krvi (glejte spodaj - poglavje
(≥ 1/1000 to < 1/100); rare (≥ 1/10,000 to <1/1,000); and very rare (< 1/10,000) or not known (cannot be estimated from available data). 
< 1/100), redki (≥ 1/10.000 do < 1/1.000) in zelo redki (< 1/10.000) ali neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov) Pri vsakem organskem sistemu so neželeni učinki navedeni po padajoči resnosti.
30,000 IU (300 mg) /3 mL 
30.000 i.e. (300 mg)/3 ml
To obtain a 300 IU/mL (3 mg/mL) solution, using a 6,000 IU (60 mg) enoxaparin sodium pre-filled syringe, it is recommended to use a 50 mL infusion bag (i.e. using either normal saline solution (0.9%) or 5% dextrose in water) as follows: 
(60 mg) natrijevega enoksaparinata je priporočljivo uporabiti 50-ml infuzijsko vrečko (tj. z uporabo fiziološke raztopine (0,9 % raztopine natrijevega klorida) ali 5 % raztopine glukoze v vodi) takole:
Immuno-allergic thrombocytopeni a 
Trombocitozaβ Trombocitopenij a
Overall, the data suggest that there is no evidence for an increased risk of haemorrhage, thrombocytopenia or osteoporosis with respect to the risk observed in non-pregnant women, other than that observed in pregnant women with prosthetic heart valves (see section 4.4). 
opaženega pri nosečnicah s protetičnimi srčnimi zaklopkami, podatki v celoti pri nosečnicah ne kažejo večjega tveganja za krvavitve, trombocitopenijo ali osteoporozo v primerjavi s tveganjem, zabeleženim pri nenosečih ženskah (glejte poglavje 4.4).
4,000 IU (40 mg) /0.4 mL 
4.000 i.e. (40 mg) /0,4 ml
In patients with severe renal impairment (creatinine clearance 15-30 mL/min), since exposure of enoxaparin sodium is significantly increased, a dosage adjustment is recommended for therapeutic and prophylactic dosage ranges. 
Ker so bolniki s hudo okvaro ledvic (očistek kreatinina < 15-30 ml/min) pomembno bolj izpostavljeni natrijevemu enoksaparinatu, jim je priporočljivo prilagoditi terapevtske in profilaktične odmerke.
15,000 IU (150 mg) /1 mL 
15.000 i.e. (150 mg)/1 ml
As with other anticoagulants, haemorrhage may occur in the presence of associated risk factors such as: organic lesions liable to bleed, invasive procedures or the concomitant use of medications affecting haemostasis (see sections 4.4 and 4.5). 
Tako kot pri drugih antikoagulansih se krvavitev lahko pojavi v prisotnosti spremljajočih dejavnikov tveganja, npr.: organskih lezij, nagnjenih h krvavitvi, invazivnih posegov ali sočasne uporabe zdravil,
One 3.0 mL pen contains enoxaparin sodium 40,000 IU anti-Xa activity (equivalent to 400 mg), equivalent to 10 single doses of 4,000 IU (40 mg) enoxaparin sodium, + 45 mg benzyl alcohol in 3.0 mL water for injections 
En 3,0 ml peresnik vsebuje 40.000 i.e. aktivnosti anti-Xa natrijevega enoksaparinata (to ustreza 400 mg), kar ustreza 10 enkratnim odmerkom 4.000 i.e. (40 mg) natrijevega enoksaparinata, + 45 mg benzilalkohola v 3,0 ml vode za injekcije
In patients with severe renal impairment (creatinine clearance <30 mL/min), the AUC at steady state is significantly increased on average by 65% after repeated SC 4,000 IU (40 mg) once daily doses (see section 4.4). 
Pri bolnikih s hudo okvaro ledvic (očistek kreatinina < 30 ml/min) je AUC v stanju dinamičnega ravnovesja bistveno večja, povprečno za 65 % po večkratni subkutani uporabi odmerkov 4.000 i.e. (40
One vial (3.0 mL) contains 30,000 IU (300 mg) enoxaparin sodium One vial (5.0 mL) contains 50,000 IU (500 mg) enoxaparin sodium One vial (10.0 mL) contains 100,000 IU (1,000 mg) enoxaparin sodium 
Ena viala (3,0 ml) vsebuje 30,000 i.e. (300 mg) natrijevega enoksaparinata Ena viala (5,0 ml) vsebuje 50,000 i.e. (500 mg) natrijevega enoksaparinata Ena viala (10,0 ml) vsebuje 100,000 i.e. (1.000 mg) natrijevega enoksaparinata
• Medicinal products affecting haemostasis (see section 4.4) It is recommended that some agents which affect haemostasis should be discontinued prior to enoxaparin sodium therapy unless strictly indicated. 
Pred začetkom zdravljenja z natrijevim enoksaparinatom je priporočljivo opustiti nekatera zdravila, ki vplivajo na hemostazo, če niso strogo indicirana.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER BOX 10,000 IU/10 mL (100 mg/10 mL) VIAL 
PODATKI NA ZUNANJI OVOJNINI ŠKATLA ZA 10.000 i.e./10 mL (100 mg/10 mL) VIALO
6,000 IU (60 mg) /0.6 mL 
6.000 i.e. (60 mg) /0,6 ml
OUTER BOX PRE FILLED SYRINGE 
ŠKATLA ZA NAPOLNJENO INJEKCIJSKO BRIZGO
VTE = venous thromboembolic event (DVT and/or PE) *The 95% Confidence Intervals for the treatment differences for total VTE were: - Enoxaparin sodium once a day versus heparin (-3.0 to 3.5) - enoxaparin sodium every 12 hours versus heparin (-4.2 to 1.7). 
*95-odstotna intervala zaupanja za razliko med zdravljenji za vse VTE sta bila: - natrijev enoksaparinat enkrat na dan v primerjavi s heparinom (-3,0 do 3,5) - natrijev enoksaparinat na 12 ur v primerjavi s heparinom (-4,2 do 1,7)
• LOVENOX (and associated names) is added to the tube leaving the body (arterial line) at the start of the dialysis session. 
• Zdravilo LOVENOX (in povezana imena) se na začetku dialize da v cevko, ki vodi iz telesa (v arterijsko linijo).
For patients with creatinine clearance [15-30 mL/minute], additional considerations are necessary because elimination of enoxaparin sodium is more prolonged. 
Pri bolnikih z očistkom kreatinina od 15 do 30 ml/min je potreben dodaten preudarek, ker je odstranjevanje natrijevega enoksaparinata dolgotrajnejše.
100,000 IU (1000 mg)/10 mL 
100.000 i.e. (1000 mg)/10 ml
However, since renal function is known to decline with age, elderly patients may show reduced elimination of enoxaparin sodium (see section 4.4). 
Ker pa je znano, da se delovanje ledvic s starostjo zmanjšuje, je odstranjevanje natrijevega enoksaparinata pri starejših bolnikih lahko upočasnjeno (glejte poglavje 4.4).
• If you are bleeding heavily or have a condition with a high risk of bleeding (such as stomach ulcer, recent surgery of the brain or eyes), including recent bleeding stroke. 
(npr. razjedo na želodcu, nedavno operacijo na možganih ali očeh), vključno z nedavno možgansko kapjo zaradi možganske krvavitve.
• Percutaneous coronary revascularization procedures To minimize the risk of bleeding following the vascular instrumentation during the treatment of unstable angina, NSTEMI and acute STEMI, adhere precisely to the intervals recommended between enoxaparin sodium injection doses. 
• Postopki za perkutano koronarno revaskularizacijo Za zmanjšanje nevarnost krvavitve po žilnih posegih med zdravljenjem nestabilne angine pektoris,
10,000 IU (100 mg) /1.0 mL 
10.000 i.e. (100 mg) /1,0 ml
• Common: Urticaria, pruritus, erythema 
Bolezni kože in podkožja • Pogosti: Urtikarija, srbenje, eritem
The mean maximum anti-IIa activity level is observed approximately 3 to 4 hours following SC injection and reaches 0.13 IU/mL and 0.19 IU/mL following repeated administration of 100 IU/kg (1 mg/kg) twice daily and 150 IU/kg (1.5 mg/kg) once daily, respectively. 
Povprečna največja raven aktivnosti anti-IIa se pojavi približno 3 do 4 ure po subkutanem injiciranju in doseže po večkratni uporabi 100 i.e./kg (1 mg/kg) dvakrat na dan 0,13 i.e./ml in po uporabi 150
Very common: Thrombocytosis β 
Zelo pogosti: Trombocitoza β
12,000 IU (120 mg) / 0.8 mL 
12.000 i.e. (120 mg)/0,8 ml
• you have had a heart valve fitted 
• če imate umetno srčno zaklopko
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION LOVENOX 10 x 4,000 IU (10 x 40 mg) Pen enoxaparin 
IME ZDRAVILA IN POT(I) UPORABE LOVENOX 10 x 4.000 i.e. (10 x 40 mg) peresnik enoksaparin
Prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients Individual thromboembolic risk for patients can be estimated using validated risk stratification model. 
Tveganje za trombembolijo je mogoče pri posameznem bolniku oceniti z validiranim modelom stratifikacije tveganja.
All patients also received warfarin sodium (dose adjusted according to prothrombin time to achieve an INR of 2.0 to 3.0), commencing within 72 hours of initiation of enoxaparin sodium or standard heparin therapy, and continuing for 90 days. 
(odmerek prilagojen protrombinskemu času, tako da je bilo doseženo INR od 2,0 do 3,0), z začetkom v 72 urah po uvedbi natrijevega enoksaparinata ali običajnega heparinskega zdravljenja in z nadaljevanjem 90 dni.
15,000 IU/mL (150 mg/mL) solution for injection 
15.000 i.e./ml (150 mg/ml) raztopina za injiciranje
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 3.0 mL OTHER 1. taking on …………… at ……….. …. 
DRUGI PODATKI 1. vzeti na …………… ob ……….. ….
Retroperitoneal haemorrhage : such as haematoma, ecchymosis other than at injection site, wound haematoma, haematuria, epistaxis and gastro-intestinal haemorrhage. 
Intrakranialna krvavitev, retroperitonealn a krvavitev : npr. hematom, ekhimoze drugje kot na mestu injiciranja, hematom rane, hematurija, epistaksa in gastrointestinalna krvavitev.
2,000 IU (20 mg) /0.2 mL 
2.000 i.e. (20 mg) /0,2 ml